LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

48.61 -0.92

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

47.78

Massimo

49.56

Metriche Chiave

By Trading Economics

Entrata

-14M

-130M

Vendite

-888K

143K

Margine di Profitto

-90,972.727

Dipendenti

437

EBITDA

-12M

-142M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+68.1% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

637M

4.7B

Apertura precedente

49.53

Chiusura precedente

48.61

Notizie sul Sentiment di mercato

By Acuity

34%

66%

96 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 dic 2025, 21:41 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 dic 2025, 14:57 UTC

Acquisizioni, Fusioni, Takeovers

Accenture to Acquire Cabel Industry from Fibonacci Group

24 dic 2025, 12:48 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead

24 dic 2025, 12:21 UTC

I principali Market Mover

Nike Shares Tick Up After Apple CEO Tim Cook Buys $2.9 Million of Its Stock

24 dic 2025, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dic 2025, 21:26 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dic 2025, 19:35 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

24 dic 2025, 19:35 UTC

Discorsi di Mercato

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dic 2025, 19:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

24 dic 2025, 19:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dic 2025, 19:06 UTC

Discorsi di Mercato

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 dic 2025, 19:03 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 dic 2025, 17:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

24 dic 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

24 dic 2025, 17:08 UTC

Acquisizioni, Fusioni, Takeovers

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dic 2025, 16:53 UTC

Acquisizioni, Fusioni, Takeovers

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 dic 2025, 16:31 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 dic 2025, 16:28 UTC

Acquisizioni, Fusioni, Takeovers

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 dic 2025, 16:17 UTC

Discorsi di Mercato

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 dic 2025, 15:33 UTC

Acquisizioni, Fusioni, Takeovers

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 dic 2025, 15:30 UTC

Acquisizioni, Fusioni, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dic 2025, 15:19 UTC

Acquisizioni, Fusioni, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dic 2025, 14:49 UTC

Acquisizioni, Fusioni, Takeovers

Mexico's Ollamani Sells Stake in Azteca Stadium

24 dic 2025, 14:19 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 dic 2025, 14:08 UTC

Acquisizioni, Fusioni, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dic 2025, 14:06 UTC

Discorsi di Mercato

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 dic 2025, 13:24 UTC

Discorsi di Mercato

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 dic 2025, 12:59 UTC

Acquisizioni, Fusioni, Takeovers

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dic 2025, 12:51 UTC

Acquisizioni, Fusioni, Takeovers

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

24 dic 2025, 12:38 UTC

Acquisizioni, Fusioni, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

68.1% in crescita

Previsioni per 12 mesi

Media 82.15 USD  68.1%

Alto 108 USD

Basso 45 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

13

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

96 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat